Immutep Limited (ASX:IMM)
0.2550
-0.0050 (-1.96%)
Jun 13, 2025, 4:10 PM AEST
Immutep Revenue
Immutep had revenue of 3.15M AUD in the half year ending December 31, 2024, with 86.75% growth. This brings the company's revenue in the last twelve months to 4.88M, up 24.11% year-over-year. In the fiscal year ending June 30, 2024, Immutep had annual revenue of 3.84M with 9.59% growth.
Revenue (ttm)
4.88M
Revenue Growth
+24.11%
P/S Ratio
76.33
Revenue / Employee
157.38K
Employees
31
Market Cap
372.40M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 3.84M | 336.16K | 9.59% |
Jun 30, 2023 | 3.51M | -1.21M | -25.64% |
Jun 30, 2022 | 4.71M | 851.56K | 22.04% |
Jun 30, 2021 | 3.86M | -9.88M | -71.88% |
Jun 30, 2020 | 13.74M | 8.10M | 143.72% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 24.61B |
Pro Medicus | 184.58M |
Cochlear | 2.31B |
Sonic Healthcare | 9.33B |
Telix Pharmaceuticals | 783.21M |
Ramsay Health Care | 17.12B |
Ansell | 3.00B |
Mesoblast | 9.16M |
Immutep News
- 16 days ago - Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma - GlobeNewsWire
- 4 weeks ago - Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo - Benzinga
- 5 weeks ago - Immutep Limited: Surging On Positive Head And Neck Data - Seeking Alpha
- 2 months ago - Immutep to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Immutep Quarterly Activities Report Q2 FY25 - GlobeNewsWire
- 4 months ago - Immutep Limited: Continuing To Make The Case For Eftilagimod - Seeking Alpha
- 6 months ago - Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - GlobeNewsWire
- 6 months ago - Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024 - GlobeNewsWire